Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

NCT00911560 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

374

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

BIOLOGICAL: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
BIOLOGICAL: oral β-glucan

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]